Table 5 HIV drug resistance to current ART regimen in PWH with pVL≥1000 copies/mL successfully sequenced (N = 70)

Current ART regimen	N	Interm/high resistance, all drugs in regimen	Interm/high resistance, two drugs in regimen^a	Interm/high resistance to one drug in regimen^b	Any Low-to-high Resistance^c	Susceptible to all ARVs in regimen
NNRTI + 2NRTIs	34	11 (32%)	16 (47%)	7 (21%)	34 (100%)	0
DTG + 2NRTIs^d	32	2 (6.3%)	3 (9.4%)	8 (25%)	13 (41%)	19 (59%)
Started on DTG-ART	15	1 (6.7%)	0	0	1 (7%)	14 (93%)
NNRTI to DTG-ART	17	1 (5.9%)	3 (18%)	8 (47%)	12 (71%)	5 (29%)
PI + 2NRTIs	4	1 (25%)	2 (50%)	1 (25%)	4 (100%)	0
Overall, N (%)	70	14 (20%)	21 (30%)	16 (23%)	51 (73%)	19 (27%)

ART antiretroviral therapy, ARV antiretroviral, DTG dolutegravir, EFV efavirenz, HIVDR HIV drug resistance, InSTI integrase strand transfer inhibitor, LPV lopinavir, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, NVP nevirapine, PI protease inhibitor, PR prevalence ratio, PWH persons with HIV, pVL plasma viral load.
^aIntermediate/high resistance to 2 (either both NRTIs or 1 NRTI & base [DTG/LPV/EFV/NVP]), and no HIVDR to third ARV in regimen.
^bIntermediate/high-level resistance to 1 ARV in regimen (with either low-level resistance to remaining one or no HIVDR to remaining two ARVs in regimen).
^cValues in this column represent totals of row entries from the preceding three columns (total N with intermediate/high resistance to at least one drug in the regimen); these values plus entries in the last column (N susceptible to all ARVs in regimen) equal 100% of those on a current ART regimen.
^dAmong persons on DTG-based ART, the risk of HIVDR to the NRTI backbone, adjusted for time on ART, was lower in those who started on DTG-ART compared to those who switched from NNRTI-ART to DTG-ART (unadjusted PR = 0.1 [95%CI: 0.01–0.6]; adjusted PR = 0.1 [95%CI: 0.01–0.8]).

Quick links

Search